Association of APOA5 c.553G>T polymorphism with type 2 diabetes mellitus in a Chinese population
-
Guanghua Zhai
Abstract
Background: Several independent population studies have reported that c.553G>T polymorphism of the apolipoprotein A5 gene (APOA5) is associated with hypertriglyceridaemia. The aim of this study is to investigate the association between this genetic variation and the risk of type 2 diabetes mellitus.
Methods: In this study, APOA5 c.553G>T polymorphisms in 152 healthy individuals and 71 type 2 diabetes mellitus patients were detected by PCR-restriction fragment length polymorphism and agarose electrophoresis methods, and serum levels of lipids were also estimated by biochemical methods.
Results: The frequency of T alleles in the diabetes and control groups was 0.085 and 0.049, respectively. Compared with controls, there was no significant difference in the distribution of genotype and allele frequencies of c.553G>T polymorphic sites in diabetic patients (p=0.27 and p=0.15, respectively). However, the frequency of GT and TT genotypes and the T allele in the subgroup with hypertriglyceridaemia was significantly higher than that in the subgroup with normal triglyceridaemia in both the control group (p=0.034 and p=0.014, respectively) and the diabetes group (p=0.037 and p=0.007, respectively). In the diabetes and control groups, triglyceride levels in (GT+TT) genotype individuals were significantly higher than in GG genotype individuals (p=0.001 and p=0.003, respectively), and levels of low-density lipoprotein cholesterol were also significantly higher (p=0.044 and p=0.022, respectively).
Conclusions: APOA5 c.553G>T polymorphism is not significantly associated with susceptibility to type 2 diabetes mellitus, but is associated with plasma triglyceride and low-density lipoprotein cholesterol levels.
Clin Chem Med Lab 2006;44:1313–6.
References
1. Pennacchio LA, Olivier M, Hubacek JA, Cohen JC, Cox DR, Krauss RM, et al. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 2001; 294:169–73.10.1126/science.1064852Suche in Google Scholar
2. Van der Vliet HN, Sammels MG, Leegwater AC, Levels JH, Reitsma PH, Boers W, et al. Apolipoprotein A-V: a novel apolipoprotein associated with an early phase of liver regeneration. J Biol Chem 2001; 276:44512–20.10.1074/jbc.M106888200Suche in Google Scholar
3. Van der Vliet HN, Schaap FG, Levels JH, Ottenhoff R, Looije N, Wesseling JG, et al. Adenovirus overexpression of apolipoprotein A-V reduces serum levels of triglycerides and cholesterol in mice. Biochem Biophys Res Commun 2002; 295:1156–9.10.1016/S0006-291X(02)00808-2Suche in Google Scholar
4. Kao JT, Wen HC, Chien KL, Hsu HC, Lin SW. A novel genetic variant in the apolipoprotein A5 gene is associated with hypertriglyceridemia. Hum Mol Genet 2003; 12:2533–9.10.1093/hmg/ddg255Suche in Google Scholar
5. Hubacek JA, Adamkova V, Ceska R, Poledne R, Horinek A, Vrablik M. New variants in the apolipoprotein AV gene in individuals with extreme triglyceride levels. Physiol Res 2004; 53:225–8.10.33549/physiolres.930546Suche in Google Scholar
6. Tang YB, Sun P, Guo DP, Ferro A, Ji Y, Chen Q, et al. A genetic variant c.553G>T in the apolipoprotein A5 gene is associated with an increased risk of coronary artery disease and altered triglyceride levels in a Chinese population. Atherosclerosis 2006; 185:433–7.10.1016/j.atherosclerosis.2005.06.026Suche in Google Scholar
7. Hsu LA, Ko YL, Chang CJ, Hu CF, Wu S, Teng MS, et al. Genetic variations of apolipoprotein A5 gene is associated with the risk of coronary artery disease among Chinese in Taiwan. Atherosclerosis 2006; 185:143–9.10.1016/j.atherosclerosis.2005.05.031Suche in Google Scholar
8. Yu H, Peng FF, Liu F. Experimental techniques in medical biochemistry and molecular biology. Wuhan: Wuhan University Press, 2003:140–1.Suche in Google Scholar
9. Marcais C, Bernard S, Merlin M. Severe hypertriglyceridaemia in type 2 diabetes: involvement of apoCIII Sst I polymorphism, LPL mutations and apoE3 deficiency. Diabetologia 2000; 43:1346–52.10.1007/s001250051537Suche in Google Scholar
10. Ginsberg HN. Lipoprotein physiology in nondiabetic and diabetes states. Diabetes Care 1991; 14:839–55.10.2337/diacare.14.9.839Suche in Google Scholar
11. Ginsberg HN, Huang LS. The insulin resistance syndrome: impact on lipoprotein metabolism and artherothrombosis. J Cardiovasc Risk 2000; 7:325–31.10.1177/204748730000700505Suche in Google Scholar
12. Martin S, Nicaud V, Humphries SE, Talmud PJ. Contribution of APOA5 gene variants to serum triglyceride determination and to the response to both fat and glucose tolerance challenges. Biochim Biophys Acta 2003; 1637:217–25.10.1016/S0925-4439(03)00033-4Suche in Google Scholar
13. Lai CQ, Tai ES, Tan CE, Cutter J, Chew SK, Zhu YP, et al. The apolipoprotein A5 locus is a strong determinant of serum triglyceride concentrations across ethnic groups in Singapore. J Lipid Res 2003; 44:2365–73.10.1194/jlr.M300251-JLR200Suche in Google Scholar PubMed
14. Aouizerat BE, Kulkarni M, Heilbron D, Drown D, Raskin S, Pullinger CR, et al. Genetic analysis of a polymorphism in the human apoA-V gene: effect on serum lipids. J Lipid Res 2003; 44:1167–73.10.1194/jlr.M200480-JLR200Suche in Google Scholar PubMed
15. Talmud PJ, Hawe E, Martin S, Olivier M, Miller GJ, Rubin EM, et al. Relative contribution of variation within the APO3/A4/A5 gene cluster in determining plasma triglycerides. Hum Mol Genet 2002; 11:3039–46.10.1093/hmg/11.24.3039Suche in Google Scholar PubMed
16. Pennacchio LA, Rubin EM. Apolipoprotein A5, a newly identified gene that affects plasma triglyceride levels in humans and mice. Arterioscler Thromb Vasc Biol 2003; 23:529–34.10.1161/01.ATV.0000054194.78240.45Suche in Google Scholar PubMed
17. Weinberg RB, Cook VR, Beckstead JA, Martin DD, Gallagher JW, Shelness GS, et al. Structure and interfacial properties of human apolipoprotein AV. J Biol Chem 2003; 278:34438–44.10.1074/jbc.M303784200Suche in Google Scholar PubMed
18. Jiang YD, Yen CJ, Chou WL, Kuo SS, Lee KC, Chiu KC, et al. Interaction of the G182C polymorphism in the APOA5 gene and fasting plasma glucose on plasma triglycerides in type 2 diabetic subjects. Diabet Med 2005; 22:1690–5.10.1111/j.1464-5491.2005.01715.xSuche in Google Scholar PubMed
19. Frohlich J, Dobiasova M. Fractional esterification rate of cholesterol and ratio of triglycerides to HDL-cholesterol are powerful predictors of positive findings on coronary angiography. Clin Chem 2003; 49:1873–80.10.1373/clinchem.2003.022558Suche in Google Scholar PubMed
©2006 by Walter de Gruyter Berlin New York
Artikel in diesem Heft
- Renal function – estimation of glomerular filtration rate
- Research translation: a new frontier for clinical laboratories
- Association of APOA5 c.553G>T polymorphism with type 2 diabetes mellitus in a Chinese population
- MTRR 66A>G polymorphism in relation to congenital heart defects
- Increased homocysteine in heart failure: a result of renal impairment?
- Urine flow cytometry and detection of glomerular hematuria
- Chymotrypsin effects on the determination of sperm parameters and seminal biochemistry markers
- Evaluation of cardiac involvement following major orthopedic surgery
- Increased sensitivity in detecting renal impairments by quantitative measurement of marker protein excretion compared to detection of pathological particles in urine sediment analysis
- Clinical chemistry reference values for 75-year-old apparently healthy persons
- Serum pro-hepcidin concentrations and their responses to oral iron supplementation in healthy subjects manifest considerable inter-individual variation
- Comparability of five analytical systems for the determination of triiodothyronine, thyroxine and thyroid-stimulating hormone
- Automated analysis of pleural fluid total and differential leukocyte counts with the Sysmex XE-2100
- Automation and validation of a fast method for the assessment of in vivo oxidative stress levels
- Analytical validation of the new plasma calibrated Accu-Chek® Test Strips (Roche Diagnostics)
- Use of insulin immunoassays in clinical studies involving rapid-acting insulin analogues: Bi-insulin IRMA preliminary assessment
- Analytical and clinical evaluation of a new heart-type fatty acid-binding protein automated assay
- A caveat for OV-Monitor (CA 125 antigen) measurement: something is improving, something is not
- Reply to the letter written by Dorizzi et al.
Artikel in diesem Heft
- Renal function – estimation of glomerular filtration rate
- Research translation: a new frontier for clinical laboratories
- Association of APOA5 c.553G>T polymorphism with type 2 diabetes mellitus in a Chinese population
- MTRR 66A>G polymorphism in relation to congenital heart defects
- Increased homocysteine in heart failure: a result of renal impairment?
- Urine flow cytometry and detection of glomerular hematuria
- Chymotrypsin effects on the determination of sperm parameters and seminal biochemistry markers
- Evaluation of cardiac involvement following major orthopedic surgery
- Increased sensitivity in detecting renal impairments by quantitative measurement of marker protein excretion compared to detection of pathological particles in urine sediment analysis
- Clinical chemistry reference values for 75-year-old apparently healthy persons
- Serum pro-hepcidin concentrations and their responses to oral iron supplementation in healthy subjects manifest considerable inter-individual variation
- Comparability of five analytical systems for the determination of triiodothyronine, thyroxine and thyroid-stimulating hormone
- Automated analysis of pleural fluid total and differential leukocyte counts with the Sysmex XE-2100
- Automation and validation of a fast method for the assessment of in vivo oxidative stress levels
- Analytical validation of the new plasma calibrated Accu-Chek® Test Strips (Roche Diagnostics)
- Use of insulin immunoassays in clinical studies involving rapid-acting insulin analogues: Bi-insulin IRMA preliminary assessment
- Analytical and clinical evaluation of a new heart-type fatty acid-binding protein automated assay
- A caveat for OV-Monitor (CA 125 antigen) measurement: something is improving, something is not
- Reply to the letter written by Dorizzi et al.
